Amneal Pharmaceuticals vs Royalty Pharma
Amneal Pharmaceuticals is the larger business, with $3.02bn of revenue in fiscal 2025 against $2.38bn for Royalty Pharma (1.3 times as much). Amneal Pharmaceuticals grew faster (8.0% against 5.1%). Royalty Pharma kept more of each dollar of sales as profit: a net margin of 32.4% against 2.4%.
| Latest fiscal year | Amneal PharmaceuticalsAMRX, 2025 | Royalty PharmaRPRX, 2025 |
|---|---|---|
| Revenue | $3.02bn | $2.38bn |
| Revenue growth | 8.0% | 5.1% |
| Net income | $72.1m | $771m |
| Operating margin | 13.1% | 65.6% |
| Net margin | 2.4% | 32.4% |
| Return on equity | — | 7.7% |
| Free cash flow | $270m | — |
| Cash | $282m | $619m |
| Total debt | $2.69bn | $8.95bn |
| Debt to equity | — | 92.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $1.23bn |
| Employees | 8,500 | 100 |
| Market value | $6.60bn | $36.94bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | 34 (Weak) | — |
| Insider trades, 12 months | 0 buys, 7 sales | 0 buys, 74 sales |